- Market Capitalization, $K 1,367,910
- Shares Outstanding, K 93,309
- Annual Sales, $ 59,320 K
- Annual Income, $ -255,130 K
- 60-Month Beta 2.79
- Price/Sales 24.32
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-9.21 (-38.58%)since 11/03/21
| || |
-12.09 (-45.20%)since 09/03/21
| || |
-9.77 (-39.99%)since 12/03/20
BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for...
Urovant Sciences, Inc., a wholly- owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Blood Pressure Monitoring has published the ambulatory blood pressure data on its recently-approved...
BASEL, Switzerland and LONDON, United Kingdom, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on...
Myovant Sciences (MYOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
/PRNewswire/ -- Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF),...
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 32.35% and 7.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Second fiscal quarter 2021 total revenues of $77.9 million; net product revenue from U.S. sales of ORGOVYX® of $18.7 million and MYFEMBREE® of $0.6...
BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the...
BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for...
Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today presented data on GEMTESA ® (vibegron) 75 mg in patients with overactive bladder (OAB) at the 2021 Annual Meeting...
|Myovant Sciences Ltd|
|Bioshares Biotech Clinical Trial|
|S&P Biotech SPDR|
|Dynamic Market Invesco ETF|
|USA Min Vol Small-Cap Ishares Edge MSCI ETF|
|Nasdaq Biotechnology Ishares ETF|
|3rd Resistance Point||16.72|
|2nd Resistance Point||16.16|
|1st Resistance Point||15.41|
|1st Support Level||14.10|
|2nd Support Level||13.54|
|3rd Support Level||12.79|